TOP TEN perturbations for P11049 (Homo sapiens)

Organism: Homo sapiens
Gene: P11049
Selected probe(set): 204192_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of P11049 (204192_at) across 5610 perturbations tested by GENEVESTIGATOR:

Treg activation study 1 (300min) / unstimulated regulatory T-cell sample

Relative Expression (log2-ratio):-4.08899
Number of Samples:2 / 2
Experimental Treg activation study 1 (300min)
Regulatory T-cells were stimulated for 300min with anti-CD3/anti-CD28/IL-2 (100U/ml). Treg were sorted as CD4+ CD25high cells from peripheral blood of healthy donors.
Control unstimulated regulatory T-cell sample
Unstimulated regulatory T-cell sample derived from sorted CD4+ CD25high cells from peripheral blood of healthy donors.

Treg activation study 1 (280min) / unstimulated regulatory T-cell sample

Relative Expression (log2-ratio):-3.3999758
Number of Samples:2 / 2
Experimental Treg activation study 1 (280min)
Regulatory T-cells were stimulated for 280min with anti-CD3/anti-CD28/IL-2 (100U/ml). Treg were sorted as CD4+ CD25high cells from peripheral blood of healthy donors.
Control unstimulated regulatory T-cell sample
Unstimulated regulatory T-cell sample derived from sorted CD4+ CD25high cells from peripheral blood of healthy donors.

ulcerative colitis study 11 / colorectal cancer study 13 (tvvad)

Relative Expression (log2-ratio):3.312172
Number of Samples:3 / 3
Experimental ulcerative colitis study 11
Colon biopsies derived from patients with ulcerative colitis.
Control colorectal cancer study 13 (tvvad)
Colon biopsies derived from patients with low grade tubulovillous/villous adenoma.

IL-4; GM-CSF study 1 (intermediate) / untreated monocyte sample

Relative Expression (log2-ratio):-3.3034897
Number of Samples:7 / 12
Experimental IL-4; GM-CSF study 1 (intermediate)
Monocytes, cultured with vehicle (DMSO/ethanol) and 500 U/ml IL-4 and 800 U/ml GM-CSF for 24 hours.
Control untreated monocyte sample
Freshly isolated human monocytes from healthy donors.

mycosis fungoides study 1 (tumor phase) / normal skin tissue

Relative Expression (log2-ratio):3.22577
Number of Samples:4 / 8
Experimental mycosis fungoides study 1 (tumor phase)
Lesional skin biopsies from patients with mycosis fungoides in the plaque phase.
Control normal skin tissue
Skin biopsies from healthy individuals.

EBNA2 overexpr. study 1 (24h) / control virus transfected EREB2-5 cell sample (24h)

Relative Expression (log2-ratio):-3.1885881
Number of Samples:3 / 3
Experimental EBNA2 overexpr. study 1 (24h)
EREB2-5 cell line stably transfected with the chimeric Epstein-Barr virus-encoded nuclear antigen 2 (EBNA2) and control expression plasmid coding for bacterial chloramphenicol acetyltransferase (CAT) gene and . CAT was used as a negative control. Briefly, before the CAT and EBNA2 induction, cells were maintained in RPMI media and deprived of estrogen for 3 days before doxycycline and estrogen was added. Expression of EBNA2 was induced after addition of estrogen and expression of CAT was induced by the addition of doxycycline to a final concentration of 100 ng/mL medium. Doxycycline induced cells were harvested 24 hours after induction. Because EBNA2 is essential for the proliferation of EBV-infected cells, EREB2-5 cells grow only in the presence of estrogen. Before the preparation of RNA, NGFR cells were purified by MACS separation to enrich the cells with a transcriptional response to doxycycline.
Control control virus transfected EREB2-5 cell sample (24h)
EREB2-5 cell line stably transfected with control expression plasmid coding for bacterial chloramphenicol acetyltransferase (CAT) gene. CAT was used as a negative control. Briefly, before the CAT induction, cells were maintained in RPMI media and deprived of estrogen for 3 days before doxycycline was added. Expression of CAT was induced by the addition of doxycycline to a final concentration of 100 ng/mL medium. Doxycycline induced cells were harvested 24 hours after induction. Estrogen withdrawal leads to the inactivation of EBNA2, resulting in cell cycle arrest. Before the preparation of RNA, NGFR cells were purified by MACS separation to enrich the cells with a transcriptional response to doxycycline.

kidney transplantation study 15 (8 week) / normal monocyte (CD14+) sample

Relative Expression (log2-ratio):-3.1367874
Number of Samples:2 / 5
Experimental kidney transplantation study 15 (8 week)
CD14+ monocyte samples derived from kidney transplant patients 8 weeks post-transplantation. Samples were collected 8 week after transplantation and administration of immunosuppressive therapy (day 1-4: methylprednisolone (60 mg); 3 doses: rabbit polyclonal anti-thymocyte globulin (ThymoglobulinH; 6 mg/kg); mycophenolate mofetil (CellCeptH); and tacrolimus (PrografH).
Control normal monocyte (CD14+) sample
CD14+ monocyte samples derived from healthy control subjects.

colorectal adenoma study 1 (small) / adjacent colon mucosa tissue

Relative Expression (log2-ratio):-2.8462276
Number of Samples:3 / 4
Experimental colorectal adenoma study 1 (small)
Ascending colon biopsies of colorectal adenomas (size: 1cm - 2cm).
Control adjacent colon mucosa tissue
Biopsies of ascending colon mucosa from adjacent tumor tissue.

ulcerative colitis study 11 / colorectal cancer study 14 (tvvad)

Relative Expression (log2-ratio):2.8136911
Number of Samples:3 / 2
Experimental ulcerative colitis study 11
Colon biopsies derived from patients with ulcerative colitis.
Control colorectal cancer study 14 (tvvad)
Colon biopsies derived from patients with high grade tubulovillous/villous adenoma.

Crohn's disease study 3 (baseline; non-responder; colon) / normal colon mucosa tissue

Relative Expression (log2-ratio):2.7412844
Number of Samples:7 / 6
Experimental Crohn's disease study 3 (baseline; non-responder; colon)
Colonic mucosal biopsies derived from Crohn's disease patients who are non-responders to infliximab treatment. Biopsies were taken within a week prior to the first intravenous infusion of infliximab; the response to infliximab was assessed 4 to 6 weeks after the first infliximab treatment. The response was defined as a complete mucosal healing with a decrease of at least 3 points on the histological score for Crohn's disease (CDc) and as a decrease to a Mayo endoscopic subscore of 0 or 1 with a decrease to grade 0 or 1 on the histological score for ulcerative colitis (UC). More strict response criteria were used for Crohn's ileitis (CDi). More baseline information about the patients are available in the publication.
Control normal colon mucosa tissue
Colonic mucosal biopsy from control subject obtained at the endoscopy for polyps screening.